TrumpRx.gov launches with discounted GLP-1 listings

The White House launched TrumpRx.gov on February 6, 2026, a federal website that points patients toward discounted cash prices on dozens of brand-name drugs, including the major GLP-1 medications ^[1]. The site does not sell anything itself. It acts as a portal that links out to manufacturers' own direct-to-consumer pages, where the purchase actually happens ^[2].

According to the White House, the monthly prices of Ozempic and injectable Wegovy — both semaglutide, made by Novo Nordisk — drop from $1,028 and $1,349 respectively to an average of $350, and as low as $199 depending on dose ^[1]. The Wegovy pill (oral semaglutide) falls from $1,349 to as low as $149 a month, again depending on dose ^[1]. Zepbound (tirzepatide, made by Eli Lilly) drops from $1,088 to an average of $346 and as low as $299 ^[1].

The numbers reported elsewhere are close but not identical. AJMC, writing the day before launch, described starting prices of about $1,000 for Ozempic and $1,350 for Wegovy falling to $350, and $1,086 falling to $346 for Zepbound ^[2]. It also noted an initial price of $150 for FDA-approved oral GLP-1 therapy ^[2]. Right now, 25-mg oral semaglutide (the Wegovy pill) is the only FDA-approved pill for weight loss, and it is also approved to reduce the risk of major adverse cardiovascular events ^[2].

How the site works

The prices come from "most-favored-nation" (MFN) pricing agreements between the administration and drugmakers, which are meant to bring US prices in line with the lowest paid in other developed countries ^[1]. Companies that have signed on and will offer direct-to-consumer sales through the platform include Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Genentech, Gilead Sciences, GlaxoSmithKline, Merck & Co, Novartis, Novo Nordisk, Pfizer, and Sanofi ^[2].

The biggest practical catch: purchases through TrumpRx require cash payment. As of launch, health insurance is not accepted on the site — which conflicts with some manufacturer direct-to-consumer programs that do allow insurance as payment ^[2].

Why it matters for patients

For people paying entirely out of pocket for a GLP-1 — a large group, since coverage for obesity drugs is uneven — these listed prices are far below the list prices the White House cited ^[1]. The lowest advertised tiers ($199 for semaglutide injections, $149 for the Wegovy pill, $299 for Zepbound) apply only at certain doses, so the price a given person sees depends on the dose prescribed ^[1].

But the cash-only structure cuts both ways. Experts quoted by AJMC cautioned that some Americans could end up paying more by going through the site, because many of the medications listed are already covered by insurance and some have cheaper generic versions ^[2]. A cash purchase also may not count toward a deductible or out-of-pocket maximum, and the sources do not address whether it would.

Other open questions remain. Health policy experts have noted that savings may not be realized immediately or at all, that the full details of the manufacturer deals may never be public, and that it is unclear whether the agreements survive beyond this administration ^[2]. The impact on Medicaid programs is also uncertain, and some analysts have warned about reduced investment in new drug development, particularly among small and midsize companies ^[2].

One more item worth flagging for GLP-1 watchers: orforglipron, Eli Lilly's oral GLP-1, was still under FDA review at the time of the launch. Lilly submitted a new drug application after the phase 3 ATTAIN-MAINTAIN trial showed weight loss was maintained when people switched from an injectable to the pill ^[2]. If approved, the lowest dose would start at $149 ^[2]. It is not yet known when that decision comes.

What happens next

The administration says more companies with MFN agreements will be onboarded on a rolling basis, and that additional high-cost medications will be added over time ^[1]. For people who use insurance, the White House is asking Congress to pass its "Great Healthcare Plan," which it says would codify the MFN savings and allow health plans to cover TrumpRx.gov purchases ^[1]. No timeline for congressional action is given in the sources.